Terug
Ook genoteerd als
RYLPF
OTC
Dagbereik
€ 26,61
€ 26,98
52-Weeksbereik
€ 21,48
€ 33,44
Volume
1.377.237
50D / 200D Gem.
€ 29,77
/
€ 27,47
Vorige Slotkoers
€ 26,81
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 28,6 | 0,3 |
| P/B | 2,3 | 2,9 |
| ROE % | 7,8 | 3,7 |
| Net Margin % | 5,0 | 3,8 |
| Rev Growth 5Y % | 1,0 | 10,0 |
| D/E | 0,7 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 2,27
€ 2,18 – € 2,44
|
21 B | 1 |
| FY2029 |
€ 2,04
€ 1,95 – € 2,20
|
21 B | 1 |
| FY2028 |
€ 1,94
€ 1,86 – € 2,09
|
20 B | 1 |
Belangrijkste Punten
Revenue grew 0,97% annually over 5 years — modest growth
Generating 893,00M in free cash flow
Cash machine — converts 99,78% of earnings into free cash flow
Capital efficient — spends only 1,51% of revenue on capex
Groei
Revenue Growth (5Y)
0,97%
Revenue (1Y)-1,04%
Earnings (1Y)N/A
FCF Growth (3Y)-32,11%
Kwaliteit
Return on Equity
7,80%
ROIC5,61%
Net Margin5,02%
Op. Margin7,98%
Veiligheid
Debt / Equity
0,74
Current Ratio1,32
Interest Coverage4,28
Waardering
P/E Ratio
28,63
P/B Ratio2,34
EV/EBITDA21,71
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -1,04% | Revenue Growth (3Y) | -0,93% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 0,97% | Earnings Growth (5Y) | -27,94% |
| Profitability | |||
| Revenue (TTM) | 17,83B | Net Income (TTM) | 895,00M |
| ROE | 7,80% | ROA | 3,32% |
| Gross Margin | 45,18% | Operating Margin | 7,98% |
| Net Margin | 5,02% | Free Cash Flow (TTM) | 893,00M |
| ROIC | 5,61% | FCF Growth (3Y) | -32,11% |
| Safety | |||
| Debt / Equity | 0,74 | Current Ratio | 1,32 |
| Interest Coverage | 4,28 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 28,63 | P/B Ratio | 2,34 |
| P/S Ratio | 1,44 | PEG Ratio | -0,11 |
| EV/EBITDA | 21,71 | Dividend Yield | 0,01% |
| Market Cap | 25,62B | Enterprise Value | 30,92B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17,83B | 18,02B | 18,17B | 17,83B | 17,16B |
| Net Income | 895,00M | -702,00M | -466,00M | -1,61B | 3,32B |
| EPS (Diluted) | 0,93 | -0,75 | -0,49 | -1,68 | 0,64 |
| Gross Profit | 8,06B | 7,77B | 7,45B | 7,19B | 7,17B |
| Operating Income | 1,42B | 529,00M | -115,00M | -1,53B | 553,00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 26,94B | 28,98B | 29,41B | 30,69B | 30,96B |
| Total Liabilities | 15,96B | 16,93B | 17,35B | 17,41B | 16,49B |
| Shareholders' Equity | 10,96B | 12,01B | 12,03B | 13,25B | 14,44B |
| Total Debt | 8,09B | 7,49B | 7,29B | 7,34B | 6,05B |
| Cash & Equivalents | 2,79B | 2,40B | 1,87B | 1,17B | 2,30B |
| Current Assets | 9,93B | 10,02B | 9,94B | 10,26B | 10,35B |
| Current Liabilities | 7,51B | 8,14B | 8,29B | 7,93B | 7,45B |